Antigen-based immune modulation: DNA vectors and beyond.
The ultimate goal for autoimmune immunotherapy is to achieve a specific downregulation or modification of autoaggressive immune responses while leaving in place the normal repertoire, capable of mediating antimicrobial responses. A multitude of preclinical studies, particularly during the last 15 years, raised hopes that self-antigens could be used to achieve the goal of specific immune modulation. Difficulties associated with the translation of this concept to the clinic revealed inherent limitations of antigen-based immune modulation. To increase the efficiency of antigen-dependent immune modulation, researchers started to investigate novel vectors for antigen delivery. Plasmid vectors, as opposed to protein antigens or peptides, have the ability to trigger prolonged production of limited amounts of antigen in the periphery. However, one complicating factor may be the inherent "danger" signal stimulated by the nature of the unmethylated CpG motifs on bacterial plasmid. Currently, various approaches are being explored to improve the efficacy of response while ameliorating the safety concerns of plasmids as immunotherapeutic tools. This manuscript offers a perspective on such efforts and outlines how the knowledge accumulated in the process will help scientists advance to the next generation of immunotherapeutics.
Bot
Adrian
A
AlleCure Corporation, 28903 North Avenue Paine, Valencia, CA 91355, USA. abot@allecure.com
Phillips
William J
WJ
von Herrath
Matthias
M
D000276:Adjuvants, Immunologic; D000818:Animals; D005822:Genetic Vectors; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D010455:Peptides / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D019444:Vaccines, DNA / Q000235:genetics* / Q000276:immunology
D000276:Adjuvants, Immunologic; D010455:Peptides; D011994:Recombinant Proteins; D019444:Vaccines, DNA